Hepatogenous Diabetes: A Comprehensive Overview
DOI:
https://doi.org/10.24871/2632025268-273Keywords:
Cirrhosis, diabetes, insulin resistanceAbstract
Cirrhosis is the advanced stage of liver disease, marked by the presence of liver fibrosis. Cirrhosis serves as a risk factor for various metabolic conditions, including hypoglycemia and hyperglycemia. Although the pathophysiology remains unclear, hyperglycemia can occur due to the interaction of various factors, such as insulin resistance. The prevalence of both diabetes mellitus and cirrhosis is increasing, and their interaction influences each other’s outcomes. Hepatogenous diabetes (HD) refers to diabetes mellitus that develops in patients with cirrhosis. HD is diagnosed using an oral glucose tolerance test, which typically reveals elevated postprandial blood glucose levels. The management of HD follows the same principles as diabetes mellitus treatment; however, pharmacological therapy should be individualized based on the patient’s liver function to ensure optimal outcome. The objective of this review is to provide a comprehensive discussion of HD, encompassing its pathophysiology, clinical implications, diagnostic approaches, and management strategies.ÂReferences
Elkrief L, Rautou P, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36(7):936-48.
Yen F, Hou M, Liu J, Hsu C, Hwu C. Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes. Front Med (Lausanne). 2022;9(962337).
Tolman K, Fonseca V, Dalpiaz A, Tan M. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734-43.
Kumar R. Hepatogenous diabetes: An underestimated problem of liver cirrhosis. Indian J Endocrinol Met. 2018;22:552-9.
Smith A, Baumgartner K, Bositis C. Cirrhosis: diagnosis and management. Am Fam Physician. 2019;100(12):759-70.
Kalista K, Lesmana C, Sulaiman A, Gani R, Hasan I. Clinical profile of cirrhotic patient with esophageal varices who undergo band ligation in Cipto Mangunkusumo Hospital. J Penyakit Dalam Indones. 2019;6:36-41.
Prasetya I, Hasan I, Wisnu W, Rumende C. Prevalence and profile of fibrosis in diabetic patients with non-alcoholic fatty liver disease and the associated factors. Acta Med Indones. 2017;49(2):91-98.
Orsi E, Grancini V, Menini S, Aghemo A, Pugliese G. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes? Liver Int. 2017;37(7):950-62.
Khan M, Hashim M, King J, Govender R, Mustafa H, Al Kaabi J. Epidemiology of type 2 ddiabetes - Global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10:107-11.
Lee W, Wells C, McCall J, Murphy R, Plank L. Prevalence of diabetes in liver cirrhosis: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2019;35(6):e3157.
Kumar R, Garcia-Compean D, Maji T. Hepatogenous diabetes: Knowledge, evidence, and skepticism. World J Hepatol. 2022;14(7):1291-306.
Itou M, Kawaguchi T, Taniguchi E, Sata M. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol. 2013;19(15):2298-306.
Vrieze A, Van Nood E, Holleman F, Salojarvi J, Koote RS, Bartelsman J, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterol. 2012;143(4):913-16.
Eslamparast T, Montano-Loza A, Raman M, Tandon P. Sarcopenic obesity in cirrhosis-The confluence of 2 prognostic titans. 2018;38(10):1706-17.
Boursier J, Anty R, Carette C, Cariou B, Castera L, Caussy C, et al. Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. Diabetes Metab. 2021;47(5):101272.
Chen H, Shieh J, Chang C, Chen TT, Lin J, Wu M, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013;62(4):606-15.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).